caa a22 4500 477071805 CHVBK 20180405111428.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF01691214 doi (NATIONALLICENCE)springer-10.1007/BF01691214 Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis [Elektronische Daten] [R. Haye, E. Lingaas, H. Høivik, T. Ødegård] In the treatment of acute maxillary sinusitis, azithromycin offers an advantage over phenoxymethylpenicillin in that a complete course of treatment requires drug administration once daily for only three days. In this double-blind, parallel-group, multicenter study, 438 patients with radiographically verified maxillary sinusitis were randomly assigned to receive either 500 mg azithromycin once daily for three days (221 patients) or 1.3 g phenoxymethylpenicillin three times daily for ten days (217 patients). Nasal secretion, maxillary tenderness and pain, nasal obstruction, general malaise, and hyposmia, were assessed at the start of the study and on days 4, 11, and 25 of treatment. After 11 days 58% of the patients in the azithromycin group were cured versus 51% in the penicillin group; after 25 days the cure rate was 79% versus 76%, respectively. When both cure and improvement were considered, the corresponding figures after 11 days were 97% (azithromycin) and 95% (penicillin); after 25 days they were 92% and 88%, respectively. Adverse events, predominantly gastrointestinal, occurred in 73 (33%) of the azithromycin-treated patients and in 87 (40.1%) of those treated with penicillin. No difference in efficacy was found between the two drugs in the treatment of acute maxillary sinusitis, and the adverse effects were comparable. The short duration of treatment with azithromycin offers a significant advantage over treatment with phenoxymethylpenicillin. Springer-Verlag, 1996 Haye R. Department of Otolaryngology, National Hospital, Pilestredet 32, 0027, Oslo, Norway aut Lingaas E. Department of Microbiology, National Hospital, Pilestredet 32, 0027, Oslo, Norway aut Høivik H. Elverum Medical Clinic, 2400, Elverum, Norway aut Ødegård T. Pfizer A/S, 1324, Lysaker, Norway aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/11(1996-11-01), 849-853 0934-9723 15:11<849 1996 15 10096 https://doi.org/10.1007/BF01691214 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01691214 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Haye R. Department of Otolaryngology, National Hospital, Pilestredet 32, 0027, Oslo, Norway aut NATIONALLICENCE 700 1- Lingaas E. Department of Microbiology, National Hospital, Pilestredet 32, 0027, Oslo, Norway aut NATIONALLICENCE 700 1- Høivik H. Elverum Medical Clinic, 2400, Elverum, Norway aut NATIONALLICENCE 700 1- Ødegård T. Pfizer A/S, 1324, Lysaker, Norway aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/11(1996-11-01), 849-853 0934-9723 15:11<849 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer